Literature DB >> 9422780

Processing and activation of pro-interleukin-16 by caspase-3.

Y Zhang1, D M Center, D M Wu, W W Cruikshank, J Yuan, D W Andrews, H Kornfeld.   

Abstract

Interleukin-16, a proinflammatory cytokine produced in CD8(+) lymphocytes, is synthesized as a precursor protein (pro-IL-16). It is postulated that the C-terminal region of pro-IL-16 is cleaved, releasing bioactive IL-16. To characterize IL-16 cleavage, we transfected COS cells with a cDNA encoding a approximately 50-kDa form of pro-IL-16. Transfected COS cells released a approximately 20-kDa IL-16 cleavage product shown to consist of the 121 C-terminal residues of pro-IL-16 by immunoblotting and amino acid sequencing. Cleaved IL-16, but not pro-IL-16, exhibited lymphocyte chemoattractant activity. A C-terminal approximately 20-kDa IL-16 polypeptide was also released when pro-IL-16 was treated with concanavalin A-stimulated CD8(+) lymphocyte lysate. Cleavage occurred after an Asp, suggesting involvement of a caspase (interleukin-1beta-converting enzyme/CED-3) family protease. Using recombinant caspases and granzyme B, we determined that pro-IL-16 cleavage is mediated only by caspase-3. Relevance to pro-IL-16 processing in primary lymphocytes was supported by identifying the p20 subunit of activated caspase-3 in stimulated CD8(+) lymphocytes and by inhibition of CD8(+) lymphocyte lysate-mediated cleavage with Ac-DEVD-CHO. Pro-IL-16 is a substrate for caspase-3, and cleavage by this enzyme releases biologically active IL-16 from its inactive precursor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422780     DOI: 10.1074/jbc.273.2.1144

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Comparative sequence analysis of the largest E1A proteins of human and simian adenoviruses.

Authors:  Nikita Avvakumov; Russ Wheeler; Jean Claude D'Halluin; Joe S Mymryk
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

2.  Significant Association of Interleukin-16 Genetic Variations to Taiwanese Lung Cancer.

Authors:  Meng-Feng Wu; Yun-Chi Wang; Te-Chun Shen; Wen-Shin Chang; Hsin-Ting Li; Cheng-Hsi Liao; Chi-Li Gong; Zhi-Hong Wang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  Interleukin-16 as a marker of Sézary syndrome onset and stage.

Authors:  Jillian Richmond; Marina Tuzova; Ashley Parks; Natalie Adams; Elizabeth Martin; Marianne Tawa; Lynne Morrison; Keri Chaney; Thomas S Kupper; Clara Curiel-Lewandrowski; William Cruikshank
Journal:  J Clin Immunol       Date:  2010-09-28       Impact factor: 8.317

Review 4.  Whipple's disease: a macrophage disease.

Authors:  Benoît Desnues; Melanie Ihrig; Didier Raoult; Jean-Louis Mege
Journal:  Clin Vaccine Immunol       Date:  2006-02

Review 5.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

6.  Interaction of Interleukin-16 Genotypes With Betel Quid Chewing Behavior on Oral Cancer in Taiwan.

Authors:  Liang-Chun Shih; Wen-Shin Chang; Hsu-Tung Lee; Yun-Chi Wang; Zhi-Hong Wang; Che-Yi Chao; Chien-Chih Yu; Hui-Yi Lin; Te-Chun Shen; Chien-Chung Kuo; Chia-Wen Tsai; DA-Tian Bau
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

7.  Proteolytic cleavage of PDZD2 generates a secreted peptide containing two PDZ domains.

Authors:  Man-Lung Yeung; Tammy S M Tam; Anthony C C Tsang; Kwok-Ming Yao
Journal:  EMBO Rep       Date:  2003-03-14       Impact factor: 8.807

8.  GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16 promoter in T lymphocytes.

Authors:  N Bannert; A Avots; M Baier; E Serfling; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  IL-16 promotes T. whipplei replication by inhibiting phagosome conversion and modulating macrophage activation.

Authors:  Eric Ghigo; Abdoulaye Oury Barry; Lionel Pretat; Khatoun Al Moussawi; Benoît Desnues; Christian Capo; Hardy Kornfeld; Jean-Louis Mege
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

10.  Human mid-gestation amniotic fluid contains interleukin-16 bioactivity.

Authors:  Catherine A Thornton; Judith A Holloway; Janis K Shute; John W Holloway; Norma D Diaper; John O Warner
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.